Form 4: Standard BioTools Officer Sean Mackay Disposes of Shares for Tax Obligations

Sean Mackay, SVP & Chief Business Officer of Standard BioTools Inc., disposed of 23,919 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Summary

• Sean Mackay, the Senior Vice President and Chief Business Officer of Standard BioTools Inc. (LAB), reported a transaction on May 28, 2025.
• The transaction involved the disposition of 23,919 shares of Standard BioTools common stock at a price of $1.09 per share.
• This disposition was a non-discretionary event, specifically for satisfying tax withholding obligations that arose from the vesting of restricted stock units (RSUs).
• The RSUs were originally granted to Mr. Mackay on March 21, 2025.
• Following this reported transaction, Mr. Mackay's direct beneficial ownership of Standard BioTools common stock stands at 819,157 shares.

Sentiment

Score: 5

Explanation: This Form 4 reports a routine, non-discretionary transaction related to tax withholding on vested equity compensation. It is a neutral event for the company's operational performance and does not indicate any significant positive or negative sentiment.

Positives

• The vesting of restricted stock units (RSUs) indicates that the performance or time-based conditions for this form of equity compensation have been met, reflecting the company's compensation structure for executives.
• The transaction is a routine tax withholding event, which is a standard practice for equity compensation and not a discretionary sale by the officer, suggesting no negative sentiment from the insider regarding the company's future.

Negatives

• The reporting person's direct beneficial ownership of common stock decreased by 23,919 shares due to the tax withholding.

Future Outlook

This Form 4 filing is a compliance document reporting a past transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• "The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on March 21, 2025."

Industry Context

This filing is a routine insider transaction report, common across all industries for executives receiving equity compensation. It reflects the standard process of managing tax liabilities associated with vested stock awards, rather than indicating any specific industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: The transaction represents a minor reduction in the direct beneficial ownership of an executive, but it is a non-discretionary event for tax purposes, not a sale driven by a change in investment outlook. The shares withheld reduce the number of shares that would otherwise enter the market from this specific vesting event.
• Employees: This filing reflects the standard practice of equity compensation for executives, which is a common component of remuneration packages in publicly traded companies.

Key Dates

Keywords

Standard BioTools, LAB, Sean Mackay, Form 4, SEC filing, insider transaction, stock disposition, restricted stock units, tax withholding, officer compensation